XVIII Encuentro de Cooperación Farma-Biotech

PRP-HO family: novel biologic immunomodulators



Madrid, 29 de octubre de 2019







<u>Content</u>

- 1. The Institution: IDIBELL / PurPose Biotherapeutics
- 2. The Research Group
- 3. The Product: PRP-HO family of immunomodulators
 - a) Background
 - b) Target Indications
 - c) Differential features facing the market
 - d) Innovative mechanism of action
 - e) Current status of development
 - f) IPR protection
 - g) Pitfalls & Risks to be considered
- 4. Partnering Opportunities










1. The Institution

IDIBELL, biomedical and biotechnology cluster in the life and health sciences sector











2. The Research Group

"No one can whistle a symphony. It takes an orchestra to play it"

Halford E. Luccock PIITG Group (Molecular Genetics Lab- IDIBELL)

> Ana Luque Inmaculada Serrano Javier Checa Alejandro Cuenca Marta Guevara Bryan Herrera Andreja Anžič Zhara Mohammadkarimi

COLLABORATORS AND ADVISORS:



Prof. Joan Torras (Nephrology Unit, CSUB-IDIBELL)





(CIB, CSIC, Madrid)

MEDICAMENTOS INNOVADORES Plataforma Tecnológica Española



Prof. Anna M. Blom (Lund University, Sweden)




Prof. Peter F. Zipfel (Hans Knöll Institute, Germany)





3. The Product (Background)







ADDRESS N. AN








3. The Product (Target Indications)

Autoimmune Diseases



3. The Product (Differential Features Facing the Market)

GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET OPPORTUNITIES AND FORECASTS.

2018-2025

Global Autoimmune Disease Therapeutics market is expected to reach **\$153,320** million by 2025.

Growing at a CAGR of 4.2% (2018-2025)











3. The Product (Differential Features Facing the Market)

Present anti-inflammatory and immunosuppressive drugs

- Low efficacy
- **Relevant and non-specific adverse events**




The Dangers of NSAIDS **Common Painkillers**

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

NSAIDs are responsible for more than 100.000 hospitalizations and more than 16,000 deaths in the U.S. each year.

> Some of the side effects include: Increased risk in cardiovascular problems Heart failure. Liver failure kidney failure (primarily with chronic use) Gastrointestinal complications (Ulcers) Hearing loss Allergic reaction Miscarriage NSAIDs also may increase blood pressure in patients with hypertension (high blood pressure)












Hit molecule: Immunomodulatory naturally occurring blood protein














PRP-HO7 novel mechanism of action: Immunomodulator able to "*reprogram*" key cells orchestrating the immune response

Pro-inflammatory Immunogenic





Anti-inflammatory Tolerogenic















PRP-HO7 isoform induces a anti-inflammatory, tolerogenic state in dendritic cells



Pre-clinical efficacy (I)

Systemic Lupus Erythematosus (SLE)

Lupus Nephritis




Biotherapeutic


Pre-clinical efficacy (I)

Systemic Lupus Erythematosus (II)

Comparative transcriptional profile of CYP- and PRP-HO7-treated lupus nephritis kidneys
















Pre-clinical efficacy (I) Systemic Lupus Erythematosus (III)



PRP-HO7 prevents ectopic lymphoid structures development in autoimmune lupus nephritis

-Luque et al. (2019) Kidney Int. In Press.






C.





Pre-clinical efficacy (I)


Systemic Lupus Erythematosus (IV)



Pre-clinical efficacy (I)

Systemic Lupus Erythematosus (V)

The anti-inflammatory and tolerogenic functions of PRP-HO7 restore immune homeostasis and improve autoimmune lupus pathology.













3. The Product (Current Status of Development)

Pre-clinical efficacy (II)

Inflammatory Bowel Disease
















Pre-clinical efficacy (III)

Rheumatoid Arthritis




Hindlimbs (End of study)



Biotherapeutic

3. The Product (Current Status of Development)



H2L: PRP6-HO7 - Improved biologic

- Smaller than a MoAb (< 100 kDa)
- Same immunomodulatory activity and stability tan PRP-HO7
- Non-glycosylated
- Scalable and cost-effective recombinant protein production in *E. coli*










Structural features of PRP6-HO7 vs. Monoclonal antibodies



- Symmetry
- Flexibility
- α -helix vs. β -sheet










PRP6-HO7 production (*E. coli*) Dos

Dose-response relationship in human MoDCs













Towards "personalized" medicine:


Predictive efficacy end-point functional assay for clinical trials

In vitro assay:

SLE patient blood samples:















3. The Product (IPR Protection)

PATENTS:

1- "Compositions and methods for immunomodulation" INVENTORS: (by order of signature): Aran, J.M., Olivar, R. REQUEST NO.: EP11382240 PRIORITY COUNTRY: European Union PRIORITY DATE: 15/07/11 PCT APPLICATION: PCT/EP2012/063932 (16/07/12) ENTITY: IDIBELL

2- "C4BP-based compounds for treating immunological diseases" INVENTORS: (by order of signature): Aran, J.M., Ruiz L.A., Ortiz, J., Lluch, N. REQUEST No.: EP17382187 PRIORITY COUNTRY: European Union PRIORITY DATE: 06/04/17 PCT APPLICATION: PCT/EP2018/058773 (06/07/18) ENTITY: IDIBELL

3- "Compounds for immunomodulation" INVENTORS: (by order of signature): Aran, J.M., Luque, A., Serrano, I. REQUEST No.: EP19382910 PRIORITY COUNTRY: European Union PRIORITY DATE: 17/10/19 PCT APPLICATION: ENTITY: IDIBELL









Technology.-

Lower efficacy than expected:

- Predictive efficacy endpoint assay for clinical trials developed.

- In vivo safety and efficacy have been successfully demonstrated in systemic lupus erythematosus, colitis and

rheumatoid arthritis mouse models.

- Administration in combination with other treatments (drugs, biologics,...) in patients who do not respond to a

single therapy.

- Possibility to perform pharmacological therapy (direct PRP6-HO7 administration), or cell therapy using ex vivo PRP6-HO7-conditioned DCs.

GMP Scaling up.-

We have already designed a candidate to be produced in E. coli bioreactors, being fully scalable.

Market.-

Although big pharma companies are controlling the market, PurPose Biotherapeutics' pipeline products have a new and distinctive MoA that is of interest for big pharma (licensing) to consolidate its market share.










4. Partnering Oportunities

<u>Precision medicine</u>: First-in-class immunomodulatory biologic for autoimmune diseases



Biotherapeutic

From the opportunity to the market: PRP-HO family - optimal cost/benefit)

- Market application: Biotechnology / Pharmaceuticals.

- Cooperation type: -License agreement.

- Joint further development (adaptation to specific needs):

Pre-clinical and clinical co-development

Regulatory compliance

Future scaling up

- Testing new applications.
- Joint venture agreement.
- Pre-seed and seed funding opportunities.









Thank you

